We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

3 hedge funds and large institutions have $155K invested in XTL Biopharmaceuticals in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more capital invested

Capital invested by funds: $97K → $155K (+$58K)

0.22% more ownership

Funds ownership: 0.68% → 0.9% (+0.22%)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$29.1K
2
Morgan Stanley
Morgan Stanley
New York
+$2.91K

Top Sellers

No sellers this quarter

XTLB Hedge Fund Activity: Q2 2017 in Review

3 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2017, worth a combined $155K — up 60% from $97K a quarter earlier.

Fund positioning in XTLB was balanced in Q2 2017: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $29.1K.

  • 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $155K of XTL Biopharmaceuticals stock for Q2 2017, up 60% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q2 2017 and 0 closed out.
  • The largest XTL Biopharmaceuticals buyer in Q2 2017 was UBS Group, an estimated $29.1K added.

Based on aggregated 13F filings for Q2 2017.